Astellas Pharma Inc. / OSI Pharmaceuticals

Non-Small Cell Lung Cancer (EGFR+)

Competitive Landscape

EGFR-mutant NSCLC (~15% of Western NSCLC, ~40% Asian) is a mature multi-generation TKI market now reshaped by 3rd-gen TKI + chemo combos and bispecifics. Third-generation EGFR TKI: osimertinib (Tagrisso, AstraZeneca) is the dominant 1L standard with $5.8B in 2023 per AZ IR after FLAURA/FLAURA2 — the share leader by a wide margin. Second-generation EGFR TKIs: afatinib (Gilotrif/Giotrif, Boehringer Ingelheim) and dacomitinib (Vizimpro, Pfizer) retain small 1L pockets. First-generation EGFR TKIs: erlotinib (Tarceva, Astellas/Roche) and gefitinib (Iressa, AstraZeneca) are now largely generic with legacy maintenance use; Tarceva peaked above $1.3B globally pre-LOE and is a minor contributor today. EGFR/MET bispecific mAb + chemo: amivantamab (Rybrevant, Johnson & Johnson) plus lazertinib (Lazcluze/Leclaza, JNJ/Yuhan) received FDA approval August 2024 for 1L EGFR-mutant NSCLC on MARIPOSA, directly challenging Tagrisso monotherapy. EGFR exon 20 insertion: amivantamab and mobocertinib (Exkivity, Takeda — withdrawn 2023 per Takeda notice). HER3 ADC: patritumab deruxtecan (Daiichi Sankyo/Merck) pursued post-TKI EGFRm in HERTHENA-Lung01 (CRL 2024, refile ongoing). Commercial lead takeaway: Tarceva is economically inconsequential in 2026; Astellas's OSI thesis was capitalized pre-Tagrisso. Current franchise battle is Tagrisso vs Rybrevant+Lazcluze.

Non-Small Cell Lung Cancer (NSCLC)

$428M OSI 2009 revenue (predominantly Tarceva royalty/co-promotion)

Disease Overview

Non-small cell lung cancer is the most common form of lung cancer, accounting for roughly 85% of cases. A subset of NSCLC tumors carry activating mutations in the EGFR gene, which drive uncontrolled cell growth; these mutations are more common in adenocarcinoma histology, women, never-smokers, and Asian patients, making EGFR-targeted therapy the precision approach.

Competitive Landscape

At the time of the 2010 acquisition, Tarceva (erlotinib) was a leading first-generation EGFR TKI for advanced/metastatic NSCLC after chemo failure and for first-line maintenance, and was also approved (combination with gemcitabine) for advanced pancreatic cancer. Its principal direct competitor was AstraZeneca's Iressa (gefitinib), which had been pulled from broad US use after ISEL but remained available in Asia/EU. Roche/Genentech, OSI's commercialization partner, drove the global Tarceva franchise; OSI's economics were tied to a co-promotion/royalty arrangement (biospace.com). The strategic landscape was already shifting: Pfizer's crizotinib (ALK) was advancing, Boehringer's afatinib (irreversible EGFR TKI) was in late-stage trials, and AstraZeneca was developing what would become Tagrisso (osimertinib). Astellas' acquisition gave it a top-tier US oncology platform anchored by Tarceva plus a pipeline including OSI-906 (linsitinib, IGF-1R), c-Met inhibitors, and the Prosidion DPP-4/glucokinase metabolic franchise. The deal price (55% premium, $4.0B fully diluted) was viewed as fair-to-full by RBC and Bernstein analysts, with concerns that Tarceva's exclusivity and EGFR class competition limited long-term upside.

Adrenocortical Carcinoma

Competitive Landscape

Adrenocortical Carcinoma (ACC) is ultra-rare (~1-2 per million). Mitotane (Lysodren, HRA Pharma) is the only approved targeted therapy, typically combined with cisplatin/doxorubicin/etoposide (EDP-M regimen). Investigational: linsitinib (Astellas/OSI; Phase 3 GALACCTIC failed 2011); abemaciclib (Lilly; small studies); immune checkpoint inhibitors (pembrolizumab, nivolumab) per basket trials; relacorilant (Corcept Therapeutics; CATALYST Phase 3 ongoing with nab-paclitaxel for hypercortisolism). OSI Pharmaceuticals' franchise was erlotinib (NSCLC/pancreatic); ACC was a speculative pipeline indication that did not advance post-acquisition.

Solid Tumors (Broad)

Competitive Landscape

Astellas/OSI was anchored on erlotinib (Tarceva, EGFR TKI for NSCLC and pancreatic cancer). See per-indication rows for competitor sets: erlotinib vs. gefitinib (Iressa), osimertinib (Tagrisso) in NSCLC; vs. gemcitabine/nab-paclitaxel in pancreatic. 'Solid Tumors (Broad)' is an aggregate label and should be split into specific indications before landscape authoring.